| Dysfunction of infiltrating cytotoxic CD8+ T cells within the graft promotes murine kidney allotransplant tolerance T Yokose, ES Szuter, I Rosales, MT Guinn, AS Liss, T Baba, DA Ruddy, ... The Journal of Clinical Investigation, 2024 | | 2024 |
| Tumor-driven stromal reprogramming in the pre-metastatic lymph node M Piquet, DA Ruddy, V Cremasco, J Chang F1000Research 13, 223, 2024 | | 2024 |
| Predicting metastatic transcriptomes of patient tumors with deep learning G Li, E Béal, D Sumner, GG Galli, V Cremasco, JM Korn, F Dondelinger, ... Cancer Research 84 (6_Supplement), 896-896, 2024 | | 2024 |
| INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas AMO Elbatsh, A Amin-Mansour, A Haberkorn, C Textor, N Ebel, E Renard, ... Nature cancer 5 (3), 481-499, 2024 | | 2024 |
| Defensive tolerance results in dysfunction of infiltrating cytotoxic CD8+ T cells through in situ reprogramming D Ruddy, M Piquet, Y Takahiro, L Andrew, A Alessandro Alessandrini The Journal of clinical investigation: JCI, 2024 | | 2024 |
| CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer A Prahallad, A Weiss, H Voshol, G Kerr, K Sprouffske, T Yuan, D Ruddy, ... Cancer Research 83 (24), 4130-4141, 2023 | 4 | 2023 |
| Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance JL Cotton, J Estrada Diez, V Sagar, J Chen, M Piquet, J Alford, Y Song, ... Cancer Research 83 (21), 3611-3623, 2023 | 1 | 2023 |
| Targeting the IL1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses R Diwanji, NA O'Brien, JE Choi, B Nguyen, T Laszewski, AL Grauel, Z Yan, ... Cancer Immunology Research 11 (6), 777-791, 2023 | 9 | 2023 |
| Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients … CD Weekes, DT Ting, AR Parikh, S Ittershagen, C Fabre, V Cremasco, ... Journal of Clinical Oncology 41 (4_suppl), TPS762-TPS762, 2023 | | 2023 |
| Mechanisms of tumor resistance to clinically relevant KRASG12C and SHP2 inhibitor combination in preclinical models of non-small cell lung cancer A Prahallad, A Weiss, J Voshol, G Kerr, T Yuan, D Ruddy, ... Mechanisms of tumor resistance to clinically relevant KRASG12C and SHP2 …, 2023 | | 2023 |
| CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses RD Molony, T Funk, G Trabucco, E Corcoran, D Ruddy, M Varadarajan, ... Frontiers in immunology 13, 909979, 2022 | 1 | 2022 |
| USING PATIENT-DERIVED XENOGRAFTS TO DISCOVER BIOMARKER-GUIDED TREATMENTS AC Palmer, D Plana, H Gao, JM Korn, G Yang, J Green, X Zhang, ... Clinical trial data science to advance precision oncology, 128, 2022 | | 2022 |
| Exquisite sensitivity to dual BRG1/BRM ATPase inhibitors reveals broad SWI/SNF dependencies in acute myeloid leukemia F Rago, LU Rodrigues, M Bonney, K Sprouffske, E Kurth, GN Elliott, ... Molecular cancer research 20 (3), 361-372, 2022 | 27 | 2022 |
| Harnessing Drivers of Pancreatic Cancer Plasticity for Therapeutic Intent D Ruddy, V Cremasco, J Chang, M Piquet, S Ittershagen Figures to be submitted as part of a P01 grant, 2022 | | 2022 |
| The OHANA Project: Target Cancer, One Cell at a Time D Ruddy, A Liss, V Cremasco, J Harrison, J Chang, S Dimitrieva, M Piquet, ... PANCREAS 50 (7), 1093-1093, 2021 | | 2021 |
| RAF-mutant melanomas differentially depend on ERK2 over ERK1 to support aberrant MAPK pathway activation and cell proliferation MS Crowe, T Zavorotinskaya, CF Voliva, MD Shirley, Y Wang, DA Ruddy, ... Molecular Cancer Research 19 (6), 1063-1075, 2021 | 3 | 2021 |
| Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment HQ Wang, IJ Mulford, F Sharp, J Liang, S Kurtulus, G Trabucco, DS Quinn, ... Cancer Research 81 (11), 3079-3091, 2021 | 40 | 2021 |
| SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms Y Wang, M Mohseni, A Grauel, JE Diez, W Guan, S Liang, JE Choi, M Pu, ... Scientific reports 11 (1), 1399, 2021 | 48 | 2021 |
| Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms V Apfel, D Begue, V Cordo’, L Holzer, L Martinuzzi, A Buhles, G Kerr, ... ACS Pharmacology & Translational Science 4 (1), 327-337, 2021 | 16 | 2021 |
| A CRISPR screen reveals resistance mechanisms to CD3-bispecific antibody therapy SQ Liu, A Grantham, C Landry, B Granda, R Chopra, S Chakravarthy, ... Cancer immunology research 9 (1), 34-49, 2021 | 9 | 2021 |
